IL162726A0 - Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections - Google Patents

Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections

Info

Publication number
IL162726A0
IL162726A0 IL16272603A IL16272603A IL162726A0 IL 162726 A0 IL162726 A0 IL 162726A0 IL 16272603 A IL16272603 A IL 16272603A IL 16272603 A IL16272603 A IL 16272603A IL 162726 A0 IL162726 A0 IL 162726A0
Authority
IL
Israel
Prior art keywords
cox
inhibitors
treatment
combination
antiviral agents
Prior art date
Application number
IL16272603A
Other languages
English (en)
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of IL162726A0 publication Critical patent/IL162726A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/027—Making masks on semiconductor bodies for further photolithographic processing not provided for in group H01L21/18 or H01L21/34

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Manufacturing & Machinery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16272603A 2002-01-10 2003-01-10 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections IL162726A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34755002P 2002-01-10 2002-01-10
PCT/US2003/000016 WO2003059347A1 (en) 2002-01-10 2003-01-10 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections

Publications (1)

Publication Number Publication Date
IL162726A0 true IL162726A0 (en) 2005-11-20

Family

ID=23364195

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16272603A IL162726A0 (en) 2002-01-10 2003-01-10 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections

Country Status (16)

Country Link
US (1) US20030211163A1 (no)
EP (1) EP1463500A1 (no)
JP (1) JP2005519061A (no)
KR (1) KR20040072720A (no)
CN (1) CN1697654A (no)
AU (1) AU2003201811A1 (no)
BR (1) BR0306820A (no)
CA (1) CA2472459A1 (no)
CO (1) CO5590913A2 (no)
IL (1) IL162726A0 (no)
MX (1) MXPA04006572A (no)
NO (1) NO20043313L (no)
PL (1) PL371252A1 (no)
RU (1) RU2004121147A (no)
WO (1) WO2003059347A1 (no)
ZA (1) ZA200404881B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
EP1206554B2 (en) 1999-08-25 2010-10-20 Allergan, Inc. Activatable recombinant neurotoxins
US20040152752A1 (en) * 2002-05-30 2004-08-05 Chong Kong Teck Treatment for human papillomavirus
CN1726018A (zh) * 2002-12-19 2006-01-25 法玛西雅公司 使用环加氧酶－2选择性抑制剂或环加氧酶－2抑制剂联合抗病毒剂治疗疱疹病毒感染的方法和组合物
WO2005055932A2 (en) 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
PE20061303A1 (es) * 2005-03-30 2006-12-07 Astion Dev As Composicion farmaceutica que comprende oxaprozina
CN104906105A (zh) * 2005-05-18 2015-09-16 Alt解决方案公司 为预防和治疗癌症对癌细胞中端粒长度的药理学调节
KR100644968B1 (ko) * 2005-10-28 2006-11-14 한국과학기술연구원 생체적합성 실리콘 나노입자의 제조 방법
WO2008036858A2 (en) 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US9675544B2 (en) 2008-01-22 2017-06-13 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
CA2721586A1 (en) * 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
IL192335A0 (en) * 2008-06-19 2011-08-01 Avivi Easy Life Ltd Antiviral compounds
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
JP2012020991A (ja) * 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
US20130203742A1 (en) 2012-02-06 2013-08-08 William L. Pridgen Valaciclovir and meloxicam combination therapy for functional somatic syndromes
TWI646091B (zh) * 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
WO2016036588A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Pharmaceutical suspensions containing etoricoxib
CN105906496A (zh) * 2016-05-16 2016-08-31 苏州毕诺佳医药技术有限公司 一种阿昔洛韦的药物组合物及其医药用途
CN117860740A (zh) * 2020-12-28 2024-04-12 中以海德人工智能药物研发股份有限公司 一种用于治疗或预防病毒性肝炎的药物组合物及其应用
EP4340884A1 (en) * 2021-05-19 2024-03-27 University of Miami Treatment of infections in and around the eye

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
CA2249009C (en) * 1996-04-12 2003-09-16 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
EP1039914A4 (en) * 1997-12-17 2007-06-27 Cornell Res Foundation Inc CYCLOOXYGENASE-2 INHIBITION
TR200103271T2 (tr) * 1999-05-14 2002-06-21 The Regents Of The University Of California İnflamasyon aracılığıyla gerçekleşen infeksiyon için anti-inflamatuar tedavi.
US20030004143A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway

Also Published As

Publication number Publication date
ZA200404881B (en) 2005-08-31
US20030211163A1 (en) 2003-11-13
RU2004121147A (ru) 2005-04-10
CA2472459A1 (en) 2003-07-24
JP2005519061A (ja) 2005-06-30
PL371252A1 (en) 2005-06-13
CN1697654A (zh) 2005-11-16
BR0306820A (pt) 2004-12-07
KR20040072720A (ko) 2004-08-18
WO2003059347A1 (en) 2003-07-24
CO5590913A2 (es) 2005-12-30
EP1463500A1 (en) 2004-10-06
MXPA04006572A (es) 2005-11-04
AU2003201811A1 (en) 2003-07-30
NO20043313L (no) 2004-10-08

Similar Documents

Publication Publication Date Title
IL162726A0 (en) Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections
NL301115I2 (nl) Drospirenon in combinatie met estetrol
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
EE200500011A (et) Indasoolid, bensotiasoolid ja bensoisotiasoolid, nende valmistamine ning kasutamine
HK1097256A1 (en) Pyrizdazine derivatives and their use as therapeutic agents
AU2003294249A8 (en) Hetero-substituted benzimidazole compounds and antiviral uses thereof
IL158985A0 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
SI1757606T1 (sl) Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
AU2003213768A8 (en) Use of benzimidazole analogs in the treatment of cell proliferation
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
EP1543034A4 (en) TREATMENT AND PROPHYLAXIS WITH 4-1BB BINDING AGENTS
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
IL173188A0 (en) Use of alcohol-oxyalkyates in the form of adjuvants for benzamidoxime gungicidal derivatives, appropriate agents and kits
GB2411354B (en) Use of Scutellaria for the treatment of viral infections
AU2003231947A8 (en) Defensins: use as antiviral agents
DE60220060D1 (de) Wirbelbildung inhibitor mit opferkörper
PL377427A1 (pl) Sposoby i kompozycje do leczenia infekcji wirusem opryszczki z zastosowaniem inhibitorów selektywnych względem cyklooksygenazy-2 lub inhibitorów cyklooksygenazy-2 w połączeniu ze środkami przeciwwirusowymi
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
EP1451183A4 (en) DIMERE COMPOUNDS AND THEIR USE AS ANTIVIRAL AGENTS
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
GB0415181D0 (en) Compounds for use in the treatment of infection